Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy

Conditions: Extensive-stage Small-cell Lung Cancer Interventions: Drug: Adebrelimab, Irinotecan Liposome (II); Drug: Adebrelimab, Irinotecan Liposome (II), Famitinib Sponsors: Baohui Han Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials